eyonis LCS Proves Safe and Effective in RELIVE Lung Cancer Study
April 1, 2025
All secondary endpoints required to support eyonis LCS’ intended use and desired marketing claims achieved in RELIVE Median Technologies manufacturer of eyonis, a suite of artificial